Table 1: Glucksberg Clinical stage of Acute GvHD 20 Table 2: Glucksberg grade of Acute GvHD 20 Table 3: Global scoring of cGvHD 21 Table 4:Diagnosed Incident Cases of Hematopoietic Stem Cell Transplantations in 7 MM (2016-2027) 28 Table 5: Diagnosed Incident Cases of aGvHD in Diagnosed Incident Cases of First Allogeneic HSCTs in 7MM- By Region(2016-2027) 29 Table 6: Diagnosed Incident Cases of cGvHD in Diagnosed Incident Cases of First Allogeneic HSCTs in 7MM- By Region (2016-2027) 30 Table 7: Diagnosed Incident Cases of Hematopoietic Stem Cell Transplantations (HSCTs) in United States (2016-2027) 38 Table 8: Diagnosed Incident Cases of Allogeneic HSCT in United States in United States (2016-2027) 39 Table 9: Diagnosed Incident Cases of aGvHD in Diagnosed Incident Cases of First Allogeneic HSCTs in United States (2016-2027) 41 Table 10: Incident cases of aGvHD by grades in United States (2016-2027) 42 Table 11: Diagnosed Incident Cases of cGvHD in Diagnosed Incident Cases of First Allogeneic HSCTs in United States (2016-2027) 44 Table 12: 4-Year Diagnosed Prevalent Cases of aGvHD in First Allogeneic HSCTs in United States (2016-2027) 45 Table 13: 5-Year Diagnosed Prevalent Cases of cGvHD in First Allogeneic HSCTs in United States (2016-2027) 46 Table 14: Diagnosed Incident Cases of Hematopoietic Stem Cell Transplantations (HSCTs) in Germany (2016-2027) 48 Table 15: Diagnosed Incident Cases of Allogeneic HSCT in Germany (2016-2027) 49 Table 16: Diagnosed Incident Cases of aGvHD in Diagnosed Incident Cases of First Allogeneic HSCTs in Germany (2016-2027) 51 Table 17: Incident cases of aGvHD by grades in Germany (2016-2027) 52 Table 18: Diagnosed Incident Cases of cGvHD in Diagnosed Incident Cases of First Allogeneic HSCTs in Germany (2016-2027) 54 Table 19: 4-Year Diagnosed Prevalent Cases of aGvHD in First Allogeneic HSCTs in Germany (2016-2027) 55 Table 20: 5-Year Diagnosed Prevalent Cases of cGvHD in First Allogeneic HSCTs in Germany (2016-2027) 56 Table 21: Diagnosed Incident Cases of Hematopoietic Stem Cell Transplantations (HSCTs) in France (2016-2027) 57 Table 22: Diagnosed Incident Cases of Allogeneic HSCT in France (2016-2027) 58 Table 23: Diagnosed Incident Cases of aGvHD in Diagnosed Incident Cases of First Allogeneic HSCTs in France (2016-2027) 59 Table 24: Incident cases of aGvHD by grades in France (2016-2027) 60 Table 25: Diagnosed Incident Cases of cGvHD in Diagnosed Incident Cases of First Allogeneic HSCTs in France (2016-2027) 61 Table 26: 4-Year Diagnosed Prevalent Cases of aGvHD in First Allogeneic HSCTs in France (2016-2027) 62 Table 27: 5-Year Diagnosed Prevalent Cases of cGvHD in First Allogeneic HSCTs in France (2016-2027) 63 Table 28: Diagnosed Incident Cases of Hematopoietic Stem Cell Transplantations (HSCTs) in Italy (2016-2027) 64 Table 29: Diagnosed Incident Cases of Allogeneic HSCT in Italy (2016-2027) 65 Table 30: Diagnosed Incident Cases of aGvHD in Diagnosed Incident Cases of First Allogeneic HSCTs in Italy (2016-2027) 67 Table 31: Incident cases of aGvHD by grades in Italy (2016-2027) 68 Table 32: Diagnosed Incident Cases of cGvHD in Diagnosed Incident Cases of First Allogeneic HSCTs in Italy (2016-2027) 69 Table 33: 4-Year Diagnosed Prevalent Cases of aGvHD in First Allogeneic HSCTs in Italy (2016-2027) 70 Table 34: 5-Year Diagnosed Prevalent Cases of cGvHD in First Allogeneic HSCTs in Italy (2016-2027) 71 Table 35: Diagnosed Incident Cases of Hematopoietic Stem Cell Transplantations (HSCTs) in Spain (2016-2027) 72 Table 36: Diagnosed Incident Cases of Allogeneic HSCT in Spain (2016-2027) 73 Table 37: Diagnosed Incident Cases of aGvHD in Diagnosed Incident Cases of First Allogeneic HSCTs in Spain (2016-2027) 74 Table 38: Incident cases of aGvHD by grades in Spain (2016-2027) 75 Table 39: Diagnosed Incident Cases of cGvHD in Diagnosed Incident Cases of First Allogeneic HSCTs in Spain (2016-2027) 76 Table 40: 4-Year Diagnosed Prevalent Cases of aGvHD in First Allogeneic HSCTs in Spain (2016-2027) 77 Table 41: 5-Year Diagnosed Prevalent Cases of cGvHD in First Allogeneic HSCTs in Spain (2016-2027) 78 Table 42: Diagnosed Incident Cases of Hematopoietic Stem Cell Transplantations (HSCTs) in United Kingdom (2016-2027) 79 Table 43: Diagnosed Incident Cases of Allogeneic HSCT in United Kingdom (2016-2027) 80 Table 44: Diagnosed Incident Cases of aGvHD in Diagnosed Incident Cases of First Allogeneic HSCTs in United Kingdom (2016-2027) 81 Table 45: Incident cases of aGvHD by grades in United Kingdom (2016-2027) 82 Table 46: Diagnosed Incident Cases of cGvHD in Diagnosed Incident Cases of First Allogeneic HSCTs in United Kingdom (2016-2027) 83 Table 47: 4-Year Diagnosed Prevalent Cases of aGvHD in First Allogeneic HSCTs in United Kingdom (2016-2027) 84 Table 48: 5-Year Diagnosed Prevalent Cases of cGvHD in First Allogeneic HSCTs in United Kingdom (2016-2027) 85 Table 49: Diagnosed Incident Cases of Hematopoietic Stem Cell Transplantations (HSCTs) in Japan (2016-2027) 87 Table 50: Diagnosed Incident Cases of Allogeneic HSCT in Japan (2016-2027) 88 Table 51: Diagnosed Incident Cases of aGvHD in Diagnosed Incident Cases of First Allogeneic HSCTs in Japan (2016-2027) 90 Table 52: Incident cases of aGvHD by grades in Japan (2016-2027) 91 Table 53: Diagnosed Incident Cases of cGvHD in Diagnosed Incident Cases of First Allogeneic HSCTs in Japan (2016-2027) 92 Table 54: 4-Year Diagnosed Prevalent Cases of aGvHD in First Allogeneic HSCTs in Japan (2016-2027) 93 Table 55: 5-Year Diagnosed Prevalent Cases of cGvHD in First Allogeneic HSCTs in Japan (2016-2027) 94 Figure 1: Pathophysiology of GvHD 22 Figure 2: Risk Factors for GvHD 23 Figure 3: Diagnosed Incident Cases of Hematopoietic Stem Cell Transplantations in 7 MM (2016-2027) 28 Figure 4: Diagnosed Incident Cases of aGvHD in Diagnosed Incident Cases of First Allogeneic HSCTs in 7MM- By Region(2016-2027) 29 Figure 5: Diagnosed Incident Cases of cGvHD in Diagnosed Incident Cases of First Allogeneic HSCTs in 7MM- By Region(2016-2027) 30 Figure 6: Diagnosed Incident Cases of Hematopoietic Stem Cell Transplantations (HSCTs) in United States (2016-2027) 38 Figure 7: Diagnosed Incident Cases of Allogeneic HSCT in United States (2016-2027) 39 Figure 8: Diagnosed Incident Cases of aGvHD in Diagnosed Incident Cases of First Allogeneic HSCTs in United States (2016-2027) 41 Figure 9: Incident cases of aGvHD by grades in United States (2016-2027) 42 Figure 10: Diagnosed Incident Cases of cGvHD in Diagnosed Incident Cases of First Allogeneic HSCTs in United States (2016-2027) 44 Figure 11: 4-Year Diagnosed Prevalent Cases of aGvHD in First Allogeneic HSCTs in United States (2016-2027) 45 Figure 12: 5-Year Diagnosed Prevalent Cases of cGvHD in First Allogeneic HSCTs in United States (2016-2027) 46 Figure 13: Diagnosed Incident Cases of Hematopoietic Stem Cell Transplantations (HSCTs) in Germany (2016-2027) 48 Figure 14: Diagnosed Incident Cases of Allogeneic HSCT in Germany (2016-2027) 49 Figure 15: Diagnosed Incident Cases of aGvHD in Diagnosed Incident Cases of First Allogeneic HSCTs in Germany (2016-2027) 51 Figure 16: Incident cases of aGvHD by grades in Germany (2016-2027) 52 Figure 17: Diagnosed Incident Cases of cGvHD in Diagnosed Incident Cases of First Allogeneic HSCTs in Germany (2016-2027) 54 Figure 18: 4-Year Diagnosed Prevalent Cases of aGvHD in First Allogeneic HSCTs in Germany (2016-2027) 55 Figure 19: 5-Year Diagnosed Prevalent Cases of cGvHD in First Allogeneic HSCTs in Germany (2016-2027) 56 Figure 20: Diagnosed Incident Cases of Hematopoietic Stem Cell Transplantations (HSCTs) in France (2016-2027) 57 Figure 21: Diagnosed Incident Cases of Allogeneic HSCT in France (2016-2027) 58 Figure 22: Diagnosed Incident Cases of aGvHD in Diagnosed Incident Cases of First Allogeneic HSCTs in France (2016-2027) 59 Figure 23: Incident cases of aGvHD by grades in France (2016-2027) 60 Figure 24: Diagnosed Incident Cases of cGvHD in Diagnosed Incident Cases of First Allogeneic HSCTs in France (2016-2027) 61 Figure 25: 4-Year Diagnosed Prevalent Cases of aGvHD in First Allogeneic HSCTs in France (2016-2027) 62 Figure 26: 5-Year Diagnosed Prevalent Cases of cGvHD in First Allogeneic HSCTs in France (2016-2027) 63 Figure 27: Diagnosed Incident Cases of Hematopoietic Stem Cell Transplantations (HSCTs) in Italy (2016-2027) 64 Figure 28: Diagnosed Incident Cases of Allogeneic HSCT in Italy (2016-2027) 65 Figure 29: Diagnosed Incident Cases of aGvHD in Diagnosed Incident Cases of First Allogeneic HSCTs in Italy (2016-2027) 67 Figure 30: Incident cases of aGvHD by grades in Italy (2016-2027) 68 Figure 31: Diagnosed Incident Cases of cGvHD in Diagnosed Incident Cases of First Allogeneic HSCTs in Italy (2016-2027) 69 Figure 32: 4-Year Diagnosed Prevalent Cases of aGvHD in First Allogeneic HSCTs in Italy (2016-2027) 70 Figure 33: 5-Year Diagnosed Prevalent Cases of cGvHD in First Allogeneic HSCTs in Italy (2016-2027) 71 Figure 34: Diagnosed Incident Cases of Hematopoietic Stem Cell Transplantations (HSCTs) in Spain (2016-2027) 72 Figure 35: Diagnosed Incident Cases of Allogeneic HSCT in Spain (2016-2027) 73 Figure 36: Diagnosed Incident Cases of aGvHD in Diagnosed Incident Cases of First Allogeneic HSCTs in Spain (2016-2027) 74 Figure 37: Incident cases of aGvHD by grades in Spain (2016-2027) 75 Figure 38: Diagnosed Incident Cases of cGvHD in Diagnosed Incident Cases of First Allogeneic HSCTs in Spain (2016-2027) 76 Figure 39: 4-Year Diagnosed Prevalent Cases of aGvHD in First Allogeneic HSCTs in Spain (2016-2027) 77 Figure 40: 5-Year Diagnosed Prevalent Cases of cGvHD in First Allogeneic HSCTs in Spain (2016-2027) 78 Figure 41: Diagnosed Incident Cases of Hematopoietic Stem Cell Transplantations (HSCTs) in United Kingdom (2016-2027) 79 Figure 42: Diagnosed Incident Cases of Allogeneic HSCT in United Kingdom (2016-2027) 80 Figure 43: Diagnosed Incident Cases of aGvHD in Diagnosed Incident Cases of First Allogeneic HSCTs in United Kingdom (2016-2027) 81 Figure 44: Incident cases of aGvHD by grades in United Kingdom (2016-2027) 82 Figure 45: Diagnosed Incident Cases of cGvHD in Diagnosed Incident Cases of First Allogeneic HSCTs in United Kingdom (2016-2027) 83 Figure 46: 4-Year Diagnosed Prevalent Cases of aGvHD in First Allogeneic HSCTs in United Kingdom (2016-2027) 84 Figure 47: 5-Year Diagnosed Prevalent Cases of cGvHD in First Allogeneic HSCTs in United Kingdom (2016-2027) 85 Figure 48: Diagnosed Incident Cases of Hematopoietic Stem Cell Transplantations (HSCTs) in Japan (2016-2027) 87 Figure 49: Diagnosed Incident Cases of Allogeneic HSCT in Japan (2016-2027) 88 Figure 50: Diagnosed Incident Cases of aGvHD in Diagnosed Incident Cases of First Allogeneic HSCTs in Japan (2016-2027) 90 Figure 51: Incident cases of aGvHD by grades in Japan (2016-2027) 91 Figure 52: Diagnosed Incident Cases of cGvHD in Diagnosed Incident Cases of First Allogeneic HSCTs in Japan (2016-2027) 92 Figure 53: 4-Year Diagnosed Prevalent Cases of aGvHD in First Allogeneic HSCTs in Japan (2016-2027) 93 Figure 54: 5-Year Diagnosed Prevalent Cases of cGvHD in First Allogeneic HSCTs in Japan (2016-2027) 94